Wuxi-based Pulnovo Medical Limited, a developer of medical devices for pulmonary hypertension and heart failure, has reportedly raised nearly USD 100 million in a Series C financing round. The funding was led by Qiming Venture Partners and Lilly Asia Ventures, with contributions from returning investors OrbiMed and Gaorong Capital.
Company Background and Product Portfolio
Pulnovo Medical was founded with a focus on the development of minimally invasive interventional therapies for hypertension and heart failure. The company has successfully commercialized its in-house developed percutaneous pulmonary artery denervation (PADN) catheters and hosts.
Funding Utilization
Pulnovo Medical plans to utilize the proceeds from the financing round to accelerate its global clinical development, expand its overseas business, and support strategic development planning.-Fineline Info & Tech
Leave a Reply